# Shree Ganesh Remedies share price today (Shree Ganesh Remedies Ltd, NSE: SGRL)

> Shree Ganesh Remedies share price today: ₹623.85 at the NSE close on 3 November 2026, up 25.8% in a year. Shree Ganesh Remedies (NSE: SGRL) is worth ₹801 crore, trades at a P/E of 66.1 and has closed between ₹423.05 and ₹709.55 over the past 52 weeks. > Shree Ganesh Remedies Ltd's share price has risen faster than its earnings: +25.8% in a year, against −23.0% for earnings per share. SGRL · Chemicals - Organic · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/shree-ganesh-remedies-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹623.85 (+25.8% in a year)
- P/E: 66.1× (higher than 90% of the last 6.2 years)
- Revenue (Sep 2026): ₹23.3 Cr (−23.2% on a year ago)
- Profit (Sep 2026): ₹1.6 Cr (−67.1% on a year ago)
- Operating margin: 16.9% (−14.8 points on a year ago)
- ROCE: 14%, FY26
- ROIC: 7.7%, against a 12.0% cost of capital: −4.3 points

The main question: the share price moved +25.8% in a year while yearly earnings per share moved −23.0%. The difference came from the market paying a higher multiple. ## What is the Shree Ganesh Remedies share price today? Shree Ganesh Remedies Ltd's share price was ₹623.85 at the close on 3 November 2026. It has been rising for 22 weeks. That is 3.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹423 and ₹710, and at that close it sat 70% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 24 weeks in a row. Over the last 9.1 years the share price moved +2,448% while the NIFTY 500 moved +144%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Shree Ganesh Remedies this quarter? Two changes stood out: lowest operating margin in 19 quarters and profit down on a year earlier for 7 quarters in a row. 1. Lowest operating margin in 19 quarters Operating margin was 16.9% in the September 2026 quarter, against 31.7% a year earlier. 2. Profit down on a year earlier for 7 quarters in a row In the September 2026 quarter profit was ₹2 crore, -67.1% on a year earlier. ## What are Shree Ganesh Remedies' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Shree Ganesh Remedies reported revenue of ₹23.3 crore, down 23.2% from ₹30.3 crore a year earlier, and a profit of ₹1.63 crore, down 67.1% from ₹4.96 crore. ### Shree Ganesh Remedies results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹23.3 crore | ₹30.3 crore | −23.2% |
| Profit | ₹1.63 crore | ₹4.96 crore | −67.1% |
| Earnings per share | ₹1.27 | ₹3.86 | −67.1% |
| Operating margin | 16.9% | 31.7% | −14.8 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 15 May 2026, about January to March 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Shree Ganesh Remedies share price history? Shree Ganesh Remedies closed at ₹623.85 on 3 November 2026, up 25.8% from ₹496.00 a year earlier (31 October 2025) and up 68.1% over five years. Its highest weekly close since October 2017 was ₹884.30 on 26 July 2024. ### Shree Ganesh Remedies share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹625.70 | −0.3% |
| 1 month ago · 1 Oct 2026 | ₹693.20 | −10.0% |
| 1 year ago · 31 Oct 2025 | ₹496.00 | +25.8% |
| 3 years ago · 3 Nov 2023 | ₹485.65 | +28.5% |
| 5 years ago · 4 Nov 2021 | ₹371.20 | +68.1% |
| Earliest and lowest weekly close in our records · 13 Oct 2017 | ₹24.48 | +2,448.4% |
| Highest weekly close since October 2017 · 26 Jul 2024 | ₹884.30 | −29.5% |
| 52-week high (weekly close) · 25 Jun 2026 | ₹709.55 | −12.1% |
| 52-week low (weekly close) · 23 Jan 2026 | ₹423.05 | +47.5% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (447 weekly closes from 13 October 2017 to 3 November 2026.)

## What is the latest news on Shree Ganesh Remedies? 3 Nov 2026: Shree Ganesh Remedies closed at ₹623.85, down 0.3% on the week and down 10.0% on the month. Results for July to September 2026: Revenue down 23.2% and profit down 67.1% on a year earlier. ### Earlier

- 15 May 2026: Shree Ganesh Remedies held its results call for January to March 2026. Management guided: Block 7 commercial production commencement July to September 2026. ## What dividend does Shree Ganesh Remedies pay? Shree Ganesh Remedies has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. Not in its latest year. Shree Ganesh Remedies Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 7 of its last 13 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Shree Ganesh Remedies management say on the latest results call? On the call for January to March 2026, held on 15 May 2026, Shree Ganesh Remedies' management guided: Block 7 commercial production commencement July to September 2026. > “We firmly believe it is the right path for the company. It is the path that will allow us to create a more sustainable and more profitable business over the long term, rather than chasing growth in commoditized segments where realizations are under structural pressure”
> Parth Kotia, Whole-time Director and CFO, on the call for January to March 2026

### What management guided

- CRAMS commercial trials expected to commence in latter half FY27 with commercial production thereafter. - No material CRAMS revenue impact in FY27; approval-stage progress anticipated. - CRAMS business expected to gain visible traction through FY27 and material ramp-up from FY28 onwards. - Sustainable long-term operating margin in 26-28% range; initial CRAMS project contributions at elevated levels before normalizing. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/31596/Conference Call/CC-May26.pdf). (From the call for January to March 2026, 15 May 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What to watch in Shree Ganesh Remedies' next results? When Shree Ganesh Remedies reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Block 7 commercial production commencement expected July to September 2026 per management guidance; track whether on track end-Q1 or experiences delays into Q3. First new capacity specifically designed for CRAMS projects represents critical path item for strategy. - What to check (from the call)
- Block 7 commercial production commencement expected July to September 2026 per management guidance; track whether on track end-Q1 or experiences delays into Q3. First new capacity specifically designed for CRAMS projects represents critical path item for strategy. - CRAMS commercial trial progress and regulatory approval advancement in H2 FY27 per management guidance; track whether projects move to commercial production phase or experience extended regulatory approval delays beyond management expectations. Customer approval timelines flagged as critical bottleneck. - Consolidated capacity utilization trajectory through FY27 from current 60-70% baseline; watch whether new CRAMS project intake and Block 7 ramp moves utilization toward peak 75-80 percent range or remains range-bound, indicating order book traction versus capacity absorption challenges. - Base business revenue and margin stability against January to March 2026 baseline; positioned as plateau by management but downside risk if competitive pressure on domestic generics intensifies further or customer deferrals persist from current environment. ## Which stock lists is Shree Ganesh Remedies on? Shree Ganesh Remedies is not on any of our India lists this week. ## Is Shree Ganesh Remedies profitable? Shree Ganesh Remedies Ltd earned ₹1.6 Cr of net profit in the Sep 2026 quarter, −67.1% on the same quarter a year earlier. Full-year FY26 profit was ₹18.0 Cr. Over 10 years profit has grown 33.5% a year on average. That is 7.0% of the quarter's revenue. The same quarter a year earlier earned ₹5.0 Cr. For the full year, FY26 profit was ₹18.0 Cr (−21.7% on the year before). Why profit moved: revenue changed −23.2% on a year earlier and the margin moved −14.8 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −45.6% and revenue −12.8%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Shree Ganesh Remedies make, and is it growing? Shree Ganesh Remedies Ltd reported ₹23.3 Cr of revenue in the Sep 2026 quarter, −23.2% on the same quarter a year earlier. Over 10 years it has grown 21.2% a year on average. The last full year, FY26, came in at ₹109 Cr. The last four reported quarters add to ₹92.0 Cr. FY26 revenue was ₹109 Cr, +0.0% on the year before. Recent pace: the last four quarters grew −12.8% on average, against 21.2% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −13.6%, against −13.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −40.7%, against −34.8% a year (rolling over). ## How much of every ₹100 of sales does Shree Ganesh Remedies keep? Shree Ganesh Remedies Ltd's operating margin was 16.9% in the Sep 2026 quarter, 14.8 percentage points lower than the same quarter a year ago. Across 13 years it has been between 12.0% and 36.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −14.8 percentage points on the year while gross margin changed +0.7 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Shree Ganesh Remedies' profit turning into cash? Over the last 3 years, 123% of Shree Ganesh Remedies Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹24.0 Cr of operating cash against ₹18.0 Cr of profit. After ₹24.0 Cr of spending on assets, ₹0.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 123% of profit came in as cash: the cash cycle got 31 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 2.7× depreciation over three years. The next section checks what that spending is building. ## Where does Shree Ganesh Remedies' cash go? Shree Ganesh Remedies Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 236 days in FY26, up from 205 days in FY21. It spent ₹71.0 Cr on assets over the last 3 years. Customers take 109 days to pay, and stock sits for 209 days on average. At FY26 sales of ₹109 Cr, each day of that cycle ties up about ₹0.3 Cr, so roughly ₹70.0 Cr is tied up in the business at any time. FY26: customers took 109 days to pay and stock sat for 209 days, about 6.9 months of sales sitting as stock, for a full cycle of 236 days, longer than FY21's 205. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 209 days. Customers pay about 109 days after that. Suppliers are paid at 82 days. Together that makes the 236-day cycle. Spending on assets: ₹71.0 Cr over the last 3 years, against ₹26.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹13.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Shree Ganesh Remedies' P/E ratio, and how does it compare with its own history? Shree Ganesh Remedies Ltd's P/E is 66.1×, near the high end of its own history: higher than 90% of past readings. Its usual P/E (the middle reading) is 35.5×, over 6.2 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −23.0% while the price moved +25.8%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +10.9% a year; about +9.6% a year came from earnings growth and about +1.3 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Shree Ganesh Remedies business getting better or worse? Shree Ganesh Remedies Ltd's business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −13.6% in the latest quarter, against +61.9% at its best in 12 quarters, with ROCE falling at 13.2%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Shree Ganesh Remedies earn on its capital? Shree Ganesh Remedies Ltd earned a ROCE of 14% in FY26. That is up from a low of 12% in FY16. Its return on capital used (ROIC) is 4.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 16.5% net margin and 0.52× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 16.5% net margin × 0.52× asset turnover × 1.28× leverage (assets divided by equity) ≈ 11.0% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 7.7% − 12.0% = −4.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 7.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 11.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Shree Ganesh Remedies have too much debt? Shree Ganesh Remedies Ltd has total debt of ₹31.0 Cr against shareholder equity of ₹163 Cr as of Jun 2026, so its debt is 0.19× its equity, which is very little. Year by year, that ratio went from 0.38 in FY23 to 0.19 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Shree Ganesh Remedies shareholding pattern? Promoters raised their stake in Shree Ganesh Remedies Ltd by 2.3 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 72.8% of the company. Domestic institutions moved +1.0 points over the same period, to 1.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +2.3 points over 8 quarters, to 72.8%; Domestic institutions: +1.0 points over 8 quarters, to 1.0%; Foreign institutions: +0.0 points over 8 quarters, to 0.0%. Why the owners changed: promoters drove it (+2.3 points), together with domestic institutions (+1.0 points). They raised their stake step by step. ## How far is Shree Ganesh Remedies from balance-sheet trouble? For Shree Ganesh Remedies Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Shree Ganesh Remedies rank in its industry? 40.3 out of 100, rank 15 of 20 in Chemicals - Organic, with 85% of the evidence available. Shree Ganesh Remedies Ltd scores 40.3 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 15. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 4.4 + 14.6 + 10.1 + 11.2 = 40.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Shree Ganesh Remedies compared with? Shree Ganesh Remedies ranks 15 of 20 Chemicals - Organic companies on the 4-Factor Sector Score, with 40.3 out of 100. 1. [Nitta Gelatin India Ltd](https://www.sectoralpha.in/stocks/nitta-gelatin-india-ltd) NITTAGELA · quiet · Most evidence points up · 85% evidence 76.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.4/35 · Revenue 15% · Profit 49.4% · Operating margin change 9 points · 100% evidence Capital efficiency 21.3/25 · ROCE 27.7% · Operating margin 28% · 100% evidence Valuation 13.2/20 · P/E 12.1× · PEG 0.95 · 100% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 35.5% · 1 year n/a · 25% evidence · 5 of 12 weeks ahead Exact sum: 30.4 + 21.3 + 13.2 + 12 = 76.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Indo Amines Ltd](https://www.sectoralpha.in/stocks/indo-amines-ltd) INDOAMIN · losing its lead · Most evidence points up · 81% evidence 66.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.8/35 · Revenue 13.3% · Profit 24.2% · Operating margin change 3 points · 88% evidence Capital efficiency 16.8/25 · ROCE 18.9% · Operating margin 14% · 100% evidence Valuation 19.0/20 · P/E 10.6× · PEG 0.32 · 100% evidence Relative strength 9.5/20 · Lead over its industry n/a · Lead over NIFTY 500 2.3% · 1 year -10.4% · 25% evidence · 4 of 12 weeks ahead Exact sum: 20.8 + 16.8 + 19 + 9.5 = 66.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Valiant Organics Ltd](https://www.sectoralpha.in/stocks/valiant-organics-ltd) VALIANTORG · breaking out · Evidence leans up · 78% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 1.5% · Profit 100% · Operating margin change 6 points · 83% evidence Capital efficiency 9.0/25 · ROCE 5.5% · Operating margin 18% · 76% evidence Valuation 10.9/20 · P/E 23.2× · PEG n/a · 50% evidence Relative strength 19.8/20 · Lead over its industry 24.1% · Lead over NIFTY 500 48.6% · 1 year 39.6% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.4 + 9 + 10.9 + 19.8 = 61.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [OCCL Ltd](https://www.sectoralpha.in/stocks/occl-ltd) OCCLLTD · breaking out · Too little evidence to rank firmly · 56% evidence 59.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 40.6% · Profit 100% · Operating margin change 7 points · 83% evidence Capital efficiency 12.3/25 · ROCE 13% · Operating margin 28% · 76% evidence Valuation 11.1/20 · P/E 11× · PEG n/a · 15% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 45.3% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 23.6 + 12.3 + 11.1 + 12.1 = 59.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [BASF India Ltd](https://www.sectoralpha.in/stocks/basf-india-ltd) BASF · quiet · Evidence leans up · 71% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 6.5% · Profit 62.4% · Operating margin change 4 points · 88% evidence Capital efficiency 11.7/25 · ROCE 14.5% · Operating margin 10% · 100% evidence Valuation 14.1/20 · P/E 21.4× · PEG n/a · 50% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -13% · 1 year -30.9% · 25% evidence · 5 of 12 weeks ahead Exact sum: 23.8 + 11.7 + 14.1 + 7.7 = 57.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Elantas Beck India Ltd](https://www.sectoralpha.in/stocks/elantas-beck-india-ltd) ELANTAS · leader · Evidence leans up · 67% evidence 57.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 18.7% · Profit 35.5% · Operating margin change 1 points · 95% evidence Capital efficiency 18.1/25 · ROCE 21.2% · Operating margin 23% · 76% evidence Valuation 6.5/20 · P/E 54.1× · PEG n/a · 50% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 31.9% · 1 year 33.1% · 25% evidence · 12 of 12 weeks ahead Exact sum: 20.7 + 18.1 + 6.5 + 11.8 = 57.1 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 7. [Fine Organic Industries Ltd](https://www.sectoralpha.in/stocks/fine-organic-industries-ltd) FINEORG · leader · Evidence leans up · 96% evidence 56.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.9/35 · Revenue 7.1% · Profit 5.8% · Operating margin change 4 points · 88% evidence Capital efficiency 17.8/25 · ROCE 21.5% · Operating margin 25% · 100% evidence Valuation 15.0/20 · P/E 35.3× · PEG 0.58 · 100% evidence Relative strength 9.9/20 · Lead over its industry -7.6% · Lead over NIFTY 500 12.4% · 1 year 13.8% · 100% evidence · 9 of 12 weeks ahead Exact sum: 13.9 + 17.8 + 15 + 9.9 = 56.6 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 8. [Laxmi Organic Industries Ltd](https://www.sectoralpha.in/stocks/laxmi-organic-industries-ltd) LXCHEM · quiet · Evidence leans up · 81% evidence 54.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 5.5% · Profit 26% · Operating margin change 7.6 points · 88% evidence Capital efficiency 10.8/25 · ROCE 4.7% · Operating margin 12% · 100% evidence Valuation 13.1/20 · P/E 33.8× · PEG 1.14 · 100% evidence Relative strength 9.2/20 · Lead over its industry n/a · Lead over NIFTY 500 1.8% · 1 year -22% · 25% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 10.8 + 13.1 + 9.2 = 54.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Balaji Amines Ltd](https://www.sectoralpha.in/stocks/balaji-amines-ltd) BALAMINES · quiet · Evidence leans up · 78% evidence 53.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.2/35 · Revenue 11.1% · Profit 41.6% · Operating margin change 10 points · 83% evidence Capital efficiency 13.1/25 · ROCE 11% · Operating margin 25% · 76% evidence Valuation 9.1/20 · P/E 28× · PEG n/a · 50% evidence Relative strength 8.2/20 · Lead over its industry -2.5% · Lead over NIFTY 500 15.2% · 1 year 25.3% · 100% evidence · 6 of 12 weeks ahead Exact sum: 23.2 + 13.1 + 9.1 + 8.2 = 53.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Fairchem Organics Ltd](https://www.sectoralpha.in/stocks/fairchem-organics-ltd) FAIRCHEMOR · quiet · Evidence leans up · 100% evidence 53.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 17.1% · Profit 100% · Operating margin change 6.2 points · 100% evidence Capital efficiency 7.0/25 · ROCE 3.3% · Operating margin 10% · 100% evidence Valuation 13.0/20 · P/E 32.7× · PEG 0.84 · 100% evidence Relative strength 3.0/20 · Lead over its industry -15.4% · Lead over NIFTY 500 3.2% · 1 year -15.9% · 100% evidence · 9 of 12 weeks ahead Exact sum: 30.3 + 7 + 13 + 3 = 53.3 · What this means: Earnings are strong; relative strength in its sector is -15.4% and the one-year return is -15.9%. 11. [Sigachi Industries Ltd](https://www.sectoralpha.in/stocks/sigachi-industries-ltd) SIGACHI · breaking out · Evidence leans down · 100% evidence 49.4 out of 100 Growth Capital Valuation Relative
12. [GFL Ltd](https://www.sectoralpha.in/stocks/gfl-ltd) GFLLIMITED · breaking out · Evidence leans down · 71% evidence 48.6 out of 100 Growth Capital Valuation Relative
13. [Jyoti Resins and Adhesives Ltd](https://www.sectoralpha.in/stocks/jyoti-resins-and-adhesives-ltd) JYOTIRES · basing · Evidence leans down · 74% evidence 43.7 out of 100 Growth Capital Valuation Relative
14. [Foseco India Ltd](https://www.sectoralpha.in/stocks/foseco-india-ltd) FOSECOIND · leader · Evidence leans down · 81% evidence 41.1 out of 100 Growth Capital Valuation Relative
15. Shree Ganesh Remedies Ltd this page SGRL · breaking out · Evidence leans down · 85% evidence 40.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 4.4/35 · Revenue -13.6% · Profit -40.7% · Operating margin change -14.8 points · 100% evidence Capital efficiency 14.6/25 · ROCE 14.1% · Operating margin 16.9% · 100% evidence Valuation 10.1/20 · P/E 65.4× · PEG 0.87 · 100% evidence Relative strength 11.2/20 · Lead over its industry n/a · Lead over NIFTY 500 16.5% · 1 year 24.4% · 25% evidence · 4 of 5 weeks ahead Exact sum: 4.4 + 14.6 + 10.1 + 11.2 = 40.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 16. [Oriental Aromatics Ltd](https://www.sectoralpha.in/stocks/oriental-aromatics-ltd) OAL · leader · Evidence leans down · 74% evidence 36.5 out of 100 Growth Capital Valuation Relative
17. [Gem Aromatics Ltd](https://www.sectoralpha.in/stocks/gem-aromatics-ltd) GEMAROMA · quiet · Too little evidence to rank firmly · 51% evidence 32.2 out of 100 Growth Capital Valuation Relative
18. [Sacheerome Ltd](https://www.sectoralpha.in/stocks/sacheerome-ltd) SACHEEROME · losing its lead · Too little evidence to rank firmly · 36% evidence 58.1 out of 100 Growth Capital Valuation Relative
19. [Shri Ahimsa Naturals Ltd](https://www.sectoralpha.in/stocks/shri-ahimsa-naturals-ltd) SHRIAHIMSA · leader · Too little evidence to rank firmly · 47% evidence 56.8 out of 100 Growth Capital Valuation Relative
20. [Citurgia Biochemicals Ltd](https://www.sectoralpha.in/stocks/citurgia-biochemicals-ltd) CITURGIA · Too little evidence to rank firmly · 25% evidence 34.3 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Chemicals - Organic](https://www.sectoralpha.in/sectors/chemicals-organic), all 20 compared on one page. ## Which companies are close to Shree Ganesh Remedies in size? Shree Ganesh Remedies is the 18th largest of 20 Chemicals - Organic companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Indo Amines, Valiant Organics, OCCL and Fairchem Organics. Just below it: Gem Aromatics and GFL. ### Chemicals - Organic companies close in size

1. [Indo Amines Ltd](https://www.sectoralpha.in/stocks/indo-amines-ltd) ₹865 crore
2. [Valiant Organics Ltd](https://www.sectoralpha.in/stocks/valiant-organics-ltd) ₹864 crore
3. [OCCL Ltd](https://www.sectoralpha.in/stocks/occl-ltd) ₹841 crore
4. [Fairchem Organics Ltd](https://www.sectoralpha.in/stocks/fairchem-organics-ltd) ₹801 crore
5. Shree Ganesh Remedies Ltd ₹792 crore
6. [Gem Aromatics Ltd](https://www.sectoralpha.in/stocks/gem-aromatics-ltd) ₹716 crore
7. [GFL Ltd](https://www.sectoralpha.in/stocks/gfl-ltd) ₹568 crore

[All 20 Chemicals - Organic companies, largest first](https://www.sectoralpha.in/sectors/chemicals-organic#all-companies)

### Companies close in size in other industries

1. [Indosolar Ltd](https://www.sectoralpha.in/stocks/indosolar-ltd) ₹797 crore · Electric Equipment - General
2. [Aptus Pharma Ltd](https://www.sectoralpha.in/stocks/aptus-pharma-ltd) ₹793 crore · Trading
3. Shree Ganesh Remedies Ltd ₹792 crore
4. [Beekay Steel Industries Ltd](https://www.sectoralpha.in/stocks/beekay-steel-industries-ltd) ₹791 crore · Steel Products
5. [Krystal Integrated Services Ltd](https://www.sectoralpha.in/stocks/krystal-integrated-services-ltd) ₹791 crore · Facility Management

## What else do people ask about Shree Ganesh Remedies? ### What were Shree Ganesh Remedies's latest quarterly results? Shree Ganesh Remedies Ltd reported revenue of ₹23.3 Cr and net profit of ₹1.6 Cr for the Sep 2026 quarter. Revenue fell 23.2% and profit fell 67.1% compared with a year earlier. Earnings per share were ₹1.27. The operating margin was 16.9%, 14.8 percentage points lower than a year earlier (as of 3 November 2026). ### What is Shree Ganesh Remedies's market cap? Shree Ganesh Remedies Ltd's market capitalisation is ₹801 Cr at a share price of ₹623.85. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Shree Ganesh Remedies performing? Shree Ganesh Remedies Ltd's share price has been rising for 22 weeks. In its latest quarter, revenue fell 23.2% and profit fell 67.1% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 24 weeks running (as of 3 November 2026). ### Will Shree Ganesh Remedies's share price go up? This page does not forecast Shree Ganesh Remedies Ltd's share price. What it shows instead: the share price is ₹623.85, and it has been rising for 22 weeks. Its P/E of 66.1× is higher than 90% of its own last 6 years (as of 3 November 2026). ### Who owns Shree Ganesh Remedies? Promoters own 72.8% of Shree Ganesh Remedies Ltd, foreign institutions 0.0%, domestic institutions 1.0% and the public 26.2% (latest quarter). The biggest change over the last two years: Promoters raised their stake by 2.3 percentage points over 8 quarters (as of 3 November 2026). ### Where is Shree Ganesh Remedies in its business cycle? Shree Ganesh Remedies Ltd's FY26 operating margin was 32.0%, against a 13-year range of 12.0% to 36.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 16.9%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Shree Ganesh Remedies story? The main question: the share price moved +25.8% in a year while yearly earnings per share moved −23.0%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Shree Ganesh Remedies a stock worth studying right now? What the numbers show: Shree Ganesh Remedies Ltd's share price has risen faster than its earnings: +25.8% in a year, against −23.0% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Shree Ganesh Remedies share price forecast for 2026? What management itself guided: Block 7 commercial production commencement July to September 2026. This is research, not advice. We’re not SEBI-registered.